Clinical trials: Dementia, Moderate
Healthy Volunteers, Moderate to Severe Alzheimer Patients
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201.
- Trial name
- NCT01513967
- Testing
- RPh201, botanical drug product
- Where
- 2 sites in Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Regenera Pharma Ltd
Alzheimer's Disease
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
This study will evaluate safety and efficacy of PF-05212377 in subjects with mild-to-moderate Alzheimer's Disease with existing neuropsychiatric symptoms on a stable dose of Donepezil.
- Trial name
- NCT01712074
- Testing
- PF-05212377 (SAM-760)
- Where
- 60 sites in United States, Canada and 5 more
- Volunteers
- 186 people
- Sponsor
- Pfizer
Alzheimer Disease
Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
The objective of this study is to determine the safety and tolerability of fosgonimeton (ATH-1017) in subjects with mild to moderate Alzheimer's disease who completed the 26-week randomized treatment in Study ATH-1017-AD-0201 or…
- Trial name
- NCT04886063
- Testing
- ATH-1017
- Where
- United States
- Volunteers
- 423 people
- Sponsor
- LeonaBio
Schizophrenia Agitation, Schizo Affective Disorder
Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder
An open-label, randomized, active control inpatient trial to evaluate the efficacy and tolerability of sublingual dexmedetomidine for the treatment of agitation in inpatients with schizophrenia or bipolar disorder as measured by…
- Conditions
- Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
- Trial name
- NCT06093451
- Testing
- Dexmedetomidine, Lorazepam 2 MG/ML
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Temple University
Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study
The purpose of this study will be to evaluate the safety and tolerability of lecanemab at sequentially ascending doses in subjects with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT01230853
- Testing
- Active Comparator: A, Active Comparator B
- Where
- 8 sites in United States
- Volunteers
- 80 people
- Sponsor
- Eisai Inc.
Alzheimer Disease
A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease
This is a 24-week prospective, randomized, double-blind, placebo-controlled, multi-center phase III study evaluating efficacy and safety of rotigotine 4mg/24 hrs in combination with rivastigmine 9.5 mg/24 hrs in mild to moderate…
- Trial name
- DOPAD-3 (NCT06702124)
- Testing
- Rotigotine 4Mg/24Hrs Patch
- Where
- Italy
- Volunteers
- 348 people
- Sponsor
- I.R.C.C.S. Fondazione Santa Lucia
Alzheimer Disease
the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease
Evaluate the Safety and Efficacy of Exosomes Derived from Allogenic Adipose Mesenchymal Stem Cells（MSCs-Exos）in Subjects with Alzheimer's disease.
- Trial name
- NCT04388982
- Testing
- low dosage MSCs-Exos administrated for nasal drip, mild dosage MSCs-Exos administrated for nasal drip, high dosage MSCs-Exos administrated for nasal drip
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Ruijin Hospital
Dementia, Alzheimer's Disease
Magnesium L-Threonate for the Enhancement of Learning and Memory in People With Dementia
The purpose of this study is to examine the effects of supplementing Magnesium L-Threonate in people with mild to moderate dementia.
- Trial name
- NCT02210286
- Testing
- Magtein
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Alzheimer's Disease
A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease
The purpose of this study is to find optimistic dose and to evaluate the efficacy and safety of SK-PC-B70M in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00443417
- Testing
- SK-PC-B70M
- Where
- South Korea
- Volunteers
- 188 people
- Sponsor
- SK Chemicals Co., Ltd.
Alzheimer's Disease
Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)
To determine the safety and tolerability of multiple ascending fixed oral doses of SRA-333 in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00151333
- Testing
- SRA-333
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Mild Dementia, Moderate Dementia
Touchscreen Technology and Art for People With Dementia in Care Homes
The prevalence of dementia is rapidly growing worldwide, affecting 46.8 million people in 2015. The 2014 Alzheimer's Society report estimated that 311,730 people with dementia were living in care homes in the United Kingdom (UK).
- Trial name
- NCT03773016
- Testing
- Art apps
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Nottingham
Alzheimer's Disease
Study to Evaluate Coconut Oil for Alzheimer's Disease
This is a randomized, cross over study to determine the efficacy of coconut oil in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT01883648
- Testing
- Coconut Oil Beverage
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of South Florida
Dementia, Alzheimer Disease 1
Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease
This is a Phase 2 study assessing the safety, tolerability and efficacy of intranasal delivery of APH-1105 for the treatment of mild to moderate Alzheimer's in adult.
- Conditions
- Dementia, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT03806478
- Testing
- APH-1105
- Volunteers
- 60 people
- Sponsor
- Aphios
Alzheimer Disease
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo.
- Trial name
- NCT00676143
- Testing
- bapineuzumab
- Where
- 288 sites in United States, Argentina and 22 more
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Alzheimer Dementia
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
This study is a multicenter, randomized, double-blind, double-dummy, active- and placebo-controlled, parallel-group clinical trial.
- Trial name
- NCT07066826
- Testing
- Huperzine A Controlled-Release Tablets, Donepezil hydrochloride tablets
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Wanbangde Pharmaceutical Group Co., LTD
Alzheimer Disease
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational vaccine, plus QS-21 in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00960531
- Testing
- ACC-001+ QS21 (3mcg), ACC-001 (10 mcg) + QS-21, ACC-001+QS-21 (30mcg)
- Where
- 28 sites in United States
- Volunteers
- 160 people
- Sponsor
- Pfizer
Alzheimer Disease
Study of STA-1 as an Add-on Treatment to Donepezil
The objective of this study is to evaluate the efficacy and safety of STA-1 vs placebo as an add-on treatment to donepezil in patients with mild to moderate Alzheimer's Disease (AD).
- Trial name
- NCT01255046
- Testing
- Donepezil,, STA-1
- Where
- Taiwan
- Volunteers
- 136 people
- Sponsor
- Sinphar Pharmaceutical Co., Ltd
Alzheimer Disease, Dementia
Faith-Based Toolbox for African Americans With Dementia
The purpose of this study is to create and test faith-based activities that might be useful for African American adults with moderate and severe dementia and their caregivers.
- Trial name
- NCT04325204
- Testing
- Faith-based Home Activity Toolbox (Faith-HAT)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Emory University
Alzheimer's Disease
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the long-term safety and tolerability of Bapineuzumab (AAB-001, ELN115727) in subjects with Alzheimer's disease who participated in study ELN115727-301 or study ELN115727-302.
- Trial name
- NCT00937352
- Testing
- Bapineuzumab
- Where
- 191 sites in United States, Austria and 1 more
- Volunteers
- 896 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer's Disease
Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)
This study will evaluate the safety and tolerability and Aß-specific antibody response of CAD106 in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00411580
- Testing
- CAD106
- Where
- 3 sites in Sweden
- Volunteers
- 58 people
- Sponsor
- Novartis Pharmaceuticals